Atomwise's JV spree

How Atomwise’s partners are thinking about deal structure for AI-driven chemistry

Drug developers signing up to partner with Atomwise for hit discovery and lead optimization said deal structures made it attractive to take the plunge on the AI company's emerging technology.

Last week, Atomwise Inc. announced three JVs with U.S.-based cancer companies and a collaboration with Chinese pharma Hansoh Pharmaceutical Group Co. Ltd. (HKEX:03692). In the last year, Atomwise has also announced partnerships with

Read the full 621 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE